The astonishing development of broad genomics and proteomics tools have catalyzed a new era in both therapeutic interventions and nutrition in prostate cancer.
The terms pharmacogenomics and nutrigenomics have been derived out of their genetic forbears as large-scale genomics technologies have been established in the last decade. It is unquestionable that rationale of both disciplines is to individualize or personalize medicine and food and nutrition, and eventually health, by tailoring the drug or the food to the individual genotype. The purpose of this review is to significantly inspect results from current research concerning the mechanisms of action of phytonutrients and potential effects on prostate cancer. Substantial emerging data supports the synergistic adiministration of nutraceuticals with TRAIL in prostate cancer progression to circumvent TRAIL refractoriness. Nonetheless, developing novel scientific methods for discovery, validation, characterization and standardization of these multicomponent phyto-therapeutics is vital to their recognition into mainstream medicine. The key to interpret a personalized response is a greater comprehension of nutrigenomics, proteomics and metabolomics.
Written by:
Farooqi AA, Rana A, Riaz AM, Khan A, Ali M, Javed S, Mukhtar S, Minhaj S, Rao JR, Rajpoot J, Amber R, Javed FA, Waqar-Un-Nisa, Khanum R, Bhatti S. Are you the author?
Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, Pakistan. .
Reference: Mol Biol Rep. 2011 Dec 6. [Epub ahead of print]
PubMed Abstract
PMID: 22143879
UroToday.com Investigational Urology Section
